Debt-to-equity of ZyVersa Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: ZyVersa Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2022 to 30 Sep 2025.
ZyVersa Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 465%, a 295% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

ZyVersa Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	465%	+347%	+295%	30 Sep 2025
Q2 2025	171%	+81%	+90%	30 Jun 2025
Q1 2025	149%	+74%	+99%	31 Mar 2025
Q4 2024	129%	+93%	+254%	31 Dec 2024
Q3 2024	118%	+92%	+354%	30 Sep 2024
Q2 2024	90%	+65%	+258%	30 Jun 2024
Q1 2024	75%	+51%	+212%	31 Mar 2024
Q4 2023	36%	+0.74%	+2.1%	31 Dec 2023
Q3 2023	26%	+159%		30 Sep 2023
Q2 2023	25%			30 Jun 2023
Q1 2023	24%			31 Mar 2023
Q4 2022	36%			31 Dec 2022
Q3 2022	-133%			30 Sep 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.